close 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Investeerimisega kaasnevad riskid ja need ei ole sobilikud kõigile investoritele. Hinnavahelepingud on keerukad instrumendid, millega kaasneb võimenduse tõttu suur risk kaotada raha kiiresti. 74% jaeinvestorite kontodest jääb antud teenusepakkuja juures hinnavahelepingutega kauplemisel kahjumisse. Palume teil kaaluda, kas hinnavahelepingute süsteem on teile arusaadav ja kas olete valmis võtma riski, mis suure tõenäoususega on kahjumlik.
Change languageEesti
Ülevaade

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

LLY

1,000.74

-0.73%↓

JNJ

243.67

+0.49%↑

ABBV

226.66

-0.51%↓

NVS

161.54

-0.79%↓

AZN

195.13

+0.21%↑

Kodu・Aktsiate loetelu・Fate Therapeutics Inc
Search

Fate Therapeutics Inc

Suletud

SektorTervishoid

1.29 -3.73

Neutraalne

Hinna uuendus 10. märts 2026, 19:53 UTC

OstaMüü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

1.28

Max

1.37

Põhinäitajad

By Trading Economics

Sissetulek

-124K

-32M

Müük

-372K

1.4M

Aktsiakasum

-0.27

Kasumimarginaal

-2,364.792

Töötajad

161

EBITDA

-13M

-42M

Soovitused

By TipRanks

Soovitused

Neutraalne

12 kuu keskmine prognoos

+69.17% upside

Dividendid

By Dow Jones

Järgmine tulemuste avaldamine

11. mai 2026

Turustatistika

By TradingEconomics

Turukapital

-20M

155M

Eelmine avamishind

5.02

Eelmine sulgemishind

1.29

Uudiste sentiment

By Acuity

20%

80%

26 / 351 Pingereas Healthcare

Tehniline skoor

By Trading Central

Kindlus

Very Strong Bearish Evidence

0.9101 / 1.14 Toetus ja vastupanu

Fate Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

10. märts 2026, 20:38 UTC

Tulu

Oracle Raises 2027 Sales Outlook Amid AI Demand, Restructuring

DJ

Loe

10. märts 2026, 23:57 UTC

Market Talk

Global Equities Roundup: Market Talk

DJ

Loe

10. märts 2026, 23:57 UTC

Market Talk

Risks Rising on Australian Bank Valuation Multiples -- Market Talk

DJ

Loe

10. märts 2026, 23:47 UTC

Market Talk

Nikkei May Rise as Concerns About Energy Costs Ease -- Market Talk

DJ

Loe

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Acquire Poseidon Stake for US$825.7M

DJ

Loe

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Buy 10% Stake in Poseidon

DJ

Loe

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Fund Deal With Internal Cash Resources

DJ

Loe

10. märts 2026, 23:37 UTC

Omandamised, ülevõtmised, äriostud

Yangzijiang Shipbuilding to Buy Stake From Fairfax, Washington Family Affiliates

DJ

Loe

10. märts 2026, 23:35 UTC

Market Talk
Uudisväärsed sündmused

Gold Edges Higher as It Faces Opposing Forces -- Market Talk

DJ

Loe

10. märts 2026, 23:06 UTC

Tulu

Oracle Raises 2027 Sales View as AI Demand Outpaces Supply -- Update

DJ

Loe

10. märts 2026, 22:51 UTC

Uudisväärsed sündmused

Deleted Tweet From Energy Secretary Sends Oil Markets on Another Wild Ride -- Updated

DJ

Loe

10. märts 2026, 21:39 UTC

Omandamised, ülevõtmised, äriostud

Bill Ackman Has a Stroke of Genius. Buy His New Fund and Get Shares of His Pershing Square IPO. -- Barrons.com

DJ

Loe

10. märts 2026, 21:21 UTC

Tulu

Oracle Stock Jumps on Earnings Beat. Its Cloud Business Is Taking Over. -- Barrons.com

DJ

Loe

10. märts 2026, 21:15 UTC

Tulu

Franco-Nevada: 2026 Total GEOs Expected to Range From 510,000 to 570,000 Ounces

DJ

Loe

10. märts 2026, 21:15 UTC

Omandamised, ülevõtmised, äriostud

Paramount Skydance's Stock Fades. The Warner Bros. Merger Will Take Years to Pay Off, BofA Says. -- Barrons.com

DJ

Loe

10. märts 2026, 21:14 UTC

Tulu

Franco-Nevada: Methodology Replaces Previous Variable GEO Conversion Ratios Based on Prevailing Market Prices

DJ

Loe

10. märts 2026, 21:13 UTC

Tulu

Franco-Nevada: Beginning in 2026, Company Will Be Adopt Fixed GEO Conversion Ratios Based on the Pricing Assumptions Outlined in 2026 Guidance

DJ

Loe

10. märts 2026, 21:12 UTC

Tulu

Franco-Nevada 4Q Rev $597.3M >FNV

DJ

Loe

10. märts 2026, 21:12 UTC

Tulu

Franco-Nevada 4Q EPS $1.90

DJ

Loe

10. märts 2026, 20:57 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

DJ

Loe

10. märts 2026, 20:50 UTC

Market Talk
Tulu

Tech, Media & Telecom Roundup: Market Talk

DJ

Loe

10. märts 2026, 20:44 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

DJ

Loe

10. märts 2026, 20:34 UTC

Market Talk
Tulu

Global Equities Roundup: Market Talk

DJ

Loe

10. märts 2026, 20:34 UTC

Market Talk
Tulu

Oracle Building More Software for Less Money After Restructuring -- Market Talk

DJ

Loe

10. märts 2026, 20:23 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

DJ

Loe

10. märts 2026, 20:16 UTC

Tulu

NIO Stock Jumps After Earnings. How the EV Maker Delivered a Surprise Profit. -- Barrons.com

DJ

Loe

10. märts 2026, 20:14 UTC

Tulu

Oracle Has Not Yet Initiated At-The-Market Equity Portion of Financing Program >ORCL

DJ

Loe

10. märts 2026, 20:14 UTC

Tulu

Oracle Said In February It Intends to Raise Up to $50 B Dollars in Debt and Equity Financing >ORCL

DJ

Loe

10. märts 2026, 20:13 UTC

Tulu

Oracle Raised $30 B Through Combination of Investment Grade Bonds and Mandatory Convertible Preferred Stk Within Days of Feb Announcement >ORCL

DJ

Loe

10. märts 2026, 20:12 UTC

Tulu

Oracle Stock Jumps on Earnings Beat -- Barrons.com

DJ

Loe

Võrdlus sarnastega

Hinnamuutus

Fate Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

69.17% tõus

12 kuu keskmine prognoos

Keskmine 2.25 USD  69.17%

Kõrge 2.5 USD

Madal 2 USD

Põhineb 4 Wall Streeti analüütiku instrumendi Fate Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

4 ratings

0

Osta

4

Hoia

0

Müü

Põhineb 4 analüütiku instrumendi Fate Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Tehniline skoor

By Trading Central

0.9101 / 1.14Toetus ja vastupanu

Lühikene perspektiiv

Very Strong Bearish Evidence

Recent bearish events outweigh bullish events.

Keskpikk perspektiiv

Very Strong Bullish Evidence

All events are bullish.

Pikk perspektiiv

No Evidence

There are no events.

Sentiment

By Acuity

26 / 351 Pingereas Tervishoid

Uudiste sentiment

Väga tugevad tõusu märgid

Volatiilsus

Alla keskmise

Uudismaht (RCV)

Alla keskmise

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

Intressikulud võla pealt

EBITDA

Ärikasum

$

Ettevõttest Fate Therapeutics Inc

Fate Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops programmed cellular immunotherapies for cancer and immune disorders worldwide. The company's chimeric antigen receptor (CAR)-targeted NK and T-cell product candidates include FT576 to treat multiple myeloma, and FT522, to treat lymphoma and autoimmune disorders. Its CAR T-cell programs include FT819 to treat hematologic malignancies and solid tumors, and FT825 to treat solid tumors. The company has a collaboration and option agreement with Ono Pharmaceutical Co. Ltd. for the development and commercialization of off-the-shelf, iPSC-derived CAR T-cell product candidates for the treatment of cancer. Fate Therapeutics, Inc. was incorporated in 2007 and is headquartered in San Diego, California.

Muud aktsiad sektorist

LLY

Eli Lilly and Co.

1,000.74

↓-0.73%

JNJ

Johnson and Johnson

243.67

↑ +0.49%

ABBV

AbbVie Inc

226.66

↓-0.51%

NVS

Novartis AG

161.54

↓-0.79%

AZN

AstraZeneca PLC

195.13

↑ +0.21%
help-icon Live chat